Accessibility Menu
Phathom Pharmaceuticals logo

Phathom Pharmaceuticals

(NASDAQ) PHAT

Current Price$10.96
Market Cap$872.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-56%
5 Year-68%
1 Year+31%
1 Month-1%
Phathom Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 10.942026-07-17
Phathom Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.24%USD 12.612026-07-10
1 month-0.55%USD 11.002026-06-17
3 month-17.06%USD 13.192026-04-17
Year to date-34.06%USD 16.592025-12-31
1 year+31.49%USD 8.322025-07-17
3 year-24.13%USD 14.422023-07-18
5 year-67.75%USD 33.922021-07-16
Since inception-55.53%USD 24.602019-10-25

Phathom Pharmaceuticals Financials at a Glance

Market Cap

$872.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$204.89M

Net Income (TTM)

-$157.30M

EPS (TTM)

-$2.11

P/E Ratio

-5.18

Dividend

$0.00

Beta (Volatility)

1.37 (Average)

Price

$10.96

Volume

16,944

Open

$11.00

Previous Close

$10.96

Daily Range

$10.92 - $11.33

52-Week Range

$7.61 - $18.31

Estimated Earnings Date

Aug 6, 2026

PHAT News

Foolcom-Featured.png

Phathom (PHAT) Q2 Revenue Jumps 441%

Motley Fool Markets TeamAug 7, 2025
Pharmaceutical factory worker

Why Shares of Phathom Pharmaceutical Jumped This Week

James HalleyJan 28, 2023

PHAT: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Phathom Pharmaceuticals

Phathom helps people with painful stomach acid and infections. Its main medicine blocks acid production better than older drugs. These products treat heartburn and bacteria that cause ulcers.

The Medicine Cabinet

  • VOQUEZNA Tablets: Oral medicine used to treat and manage acid reflux disease in adults.
  • VOQUEZNA DUAL PAK: Combination of two medications used to clear stomach bacteria called H. pylori.
  • VOQUEZNA TRIPLE PAK: Three-drug bundle containing an acid blocker and two antibiotics; accounted for about 1% of revenue in 2025.

Major Moves and Milestones

  • In 2019, the company licensed the rights to its primary drug from Takeda Pharmaceutical Company Limited.
  • Launched its first commercial products in the United States during the fourth quarter of 2023.
  • Successfully requested that the FDA extend the marketing exclusivity for its core treatment until 2032.
  • Started a Phase 2 clinical trial for a new stomach tissue condition in late 2025.

What Makes Phathom Different?

Phathom sells the only potassium-competitive acid blocker approved in the United States. This drug class represents the first major innovation in stomach acid treatment in over 30 years.

Profitability and Sales Metrics

  • Revenue rose to $58.3 million in Q1 2026, up 104.4% year-over-year.
  • Gross profit reached $46.3 million in Q1 2026, up 86.8% from Q1 2025.
  • Operating loss was $15.5 million in Q1 2026, which improved from a $78.9 million loss in Q1 2025.
  • Net loss narrowed to $30.4 million in Q1 2026, an improvement from a $94.3 million loss in Q1 2025.
  • Cash and cash equivalents totaled $180.9 million as of March 31, 2026.

The Path Ahead

Phathom has transitioned from a research firm into a commercial provider of gastrointestinal treatments. Its focus on a unique drug class allows it to challenge older, established medications in the large acid-reflux market.

AI Generated • May 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

371

CEO

Steven L. Basta, MBA

Website

www.phathompharma.com

Headquarters

Florham Park, NJ 07932, US

PHAT Financials

Key Financial Metrics (TTM)

Gross Margin

84.93%

Operating Margin

-47.15%

Net Income Margin

-76.77%

Return on Equity

39.24%

Return on Capital

N/A

Return on Assets

-51.55%

Earnings Yield

-19.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$872.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

79.76M

Volume

16.94K

Avg. Volume

1.24M

Financials (TTM)

Gross Profit

$174.02M

Operating Income

-$96.60M

EBITDA

-$90.89M

Operating Cash Flow

-$97.49M

Capital Expenditure

-$70.00K

Free Cash Flow

-$97.40M

Cash & ST Invst.

$180.90M

Total Debt

$166.30M

Phathom Pharmaceuticals Performance Analysis

Phathom Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 682,000N/A
20242024-12-31USD 55,252,0008001.5%
20252025-12-31USD 175,110,000216.9%
Phathom Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3038.5%
Q32025-09-3025.3%
Q42025-12-3116.3%
Q12026-03-311.2%
Phathom Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.0530.0%
20232023-12-31USD -3.93-22.2%
20242024-12-31USD -5.2934.6%
20252025-12-31USD -3.03-42.7%
Phathom Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.8%
Q32025-09-3061.0%
Q42025-12-3129.3%
Q12026-03-31-27.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$58.30M

+104.4%

Gross Profit

$46.31M

+86.8%

Gross Margin

79.42%

N/A

Market Cap

$872.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.35M

N/A

Employees

371

N/A

Net Income

-$30.37M

+67.8%

EBITDA

-$14.46M

+81.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$180.90M

-14.8%

Total Debt

$166.30M

-70.5%

Accounts Receivable

$80.72M

+122.0%

Inventory

$6.51M

+105.6%

Long Term Debt

$165.64M

-69.7%

Short Term Debt

$667.00K

-96.2%

Return on Assets

-51.55%

N/A

Return on Invested Capital

-53.64%

N/A

Free Cash Flow

-$15.65M

+81.6%

Operating Cash Flow

-$15.65M

+81.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SANASana Biotechnology, Inc.
$3.15-0.63%
OCSOculis Holding AG
$12.19-3.33%
BBOTBridgeBio Oncology Therapeutics Inc.
$8.56+3.01%
XNCRXencor, Inc.
$17.47+16.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%

Questions About PHAT

What is the current price of Phathom Pharmaceuticals?

Phathom Pharmaceuticals is trading at $10.96 per share.

What is the 52-week range for Phathom Pharmaceuticals?

Over the past 52 weeks, Phathom Pharmaceuticals has traded between $7.61 and $18.31.

How much debt does Phathom Pharmaceuticals have?

As of the most recent reporting period, Phathom Pharmaceuticals reported total debt of $547.22M.

How much cash does Phathom Pharmaceuticals have on hand?

Phathom Pharmaceuticals reported $180.90M in cash and cash equivalents in its most recent financial results.

What is Phathom Pharmaceuticals’s dividend yield?

Phathom Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services